There's growing evidence to suggest that GLP-1 drugs, which include semaglutide, may be useful for treating alcohol use disorder.

Now, researchers have detailed nine new reports of US patients who went blind after taking semaglutide or tirzepatide ... One woman injected one dose of semaglutide for her diabetes and woke ...

A study published to JAMA Ophthalmology detailed the experiences of nine patients - aged between 37 and 77 - who experienced eye complications after taking semaglutide or tirzepatide. "There has ...

Over the nine-week trial, participants taking semaglutide started at a dose of 0.25 mg per week, which gradually increased to 1.0 mg in the final week -- a much lower dose than what’s typically ...

Higher-dose weight loss injections now available." A new study increases max-dose guidance for semaglutide. This offers hope for those who didn’t reach their weight goals. The Injection and ...

In the first clinical trial of its kind, a weekly dose of semaglutide, also known as Ozempic and Wegovy, was found to cut the amount that people drink in one day by about 40% and dramatically ...

One FDA page now lists semaglutide as “in shortage,” while another says that all doses are available. The shortage of tirzepatide, the drug used in Mounjaro and Zepbound, is now marked ...

They were then randomly assigned to receive weekly, low-dose injections of semaglutide or a placebo for nine weeks, during which time their weekly drinking patterns were also measured. Their ...

The SELECT trial findings indicated that a dose of 2.4mg of semaglutide could help prevent a decline in renal functions in non-diabetic, obese patients with cardiovascular disease. Patients taking ...

Eli Lilly sells the other major drugs in the class, Mounjaro for diabetes and Zepbound for obesity, based on the active ingredient tirzepatide ... low-dose injections of semaglutide each week ...